<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371931">
  <stage>Registered</stage>
  <submitdate>25/01/2017</submitdate>
  <approvaldate>31/01/2017</approvaldate>
  <actrnumber>ACTRN12617000166370</actrnumber>
  <trial_identification>
    <studytitle>A randomised phase 3 trial of Palliative care Early in Advanced Lung Cancers.</studytitle>
    <scientifictitle>Efficacy of early referral to palliative care for improving quality of life and health care resources following recent diagnosis of advanced thoracic maglignancies.</scientifictitle>
    <utrn />
    <trialacronym>PEARL</trialacronym>
    <secondaryid>CTC 0145/ALTG 13/008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adults with advanced thoracic malignancy (NSCLC, SCLC or
MPM) that have been newly diagnosed within the last 60 days.</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Standard oncological care plus early referral (within 7 days of randomisation) to a
hospital-based palliative care service for the specified palliative care intervention (first consultation within 60 days of the diagnosis of advanced lung cancer or mesothelioma). The intervention is the early referral to palliative care - there is no change to the palliative care received, which is at the discretion of the treating physician until patient death.</interventions>
    <comparator>Standard oncological care plus referral to a hospital based palliative care service, the timing of which is determined at the treating clinicians discretion.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of participants with a clinically important improvement in health-related quality of life (HRQL), defined as an improvement of 5 points or more from baseline on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Trials Outcomes Index (TOI) maintained for at least 2 consecutive assessments within 6 months from randomisation.</outcome>
      <timepoint>Baseline (which is up to 7 days prior to randomisation) and every 3-4 weeks up until 24 weeks post-randomisation and then every 6-8 weeks until patient's death.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The change in quality of life using score on FACT-L TOI</outcome>
      <timepoint>Baseline compared to 12 weeks post-randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite outcome of healthcare resource use, costs and incremental cost effectiveness to determine the incremental cost-effectiveness and cost-utility of early referral to palliative care versus discretionary referral.
The following health-care resource usage will be collected for assessment: 
* Hospitalisations or emergency department presentations (for all participants by trial staff via a standard (e)CRF), 
* Visits to health professionals (for Australian participants via Medical Benefits Schedule (MBS)), and; 
* Medications (for Australian participants via Pharmaceutical Benefits Scheme (PBS)).
</outcome>
      <timepoint>From date of randomisation to death or end of trial.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite outcome of specific aspects of HRQL including depression, anxiety, lung cancer symptoms and overall HRQL (FACT-L, PROMIS-ED, EQ-5D-5L, ICECAP-SCM and patient good days diary)</outcome>
      <timepoint>The FACT-L, EQ-5D-5L and ICECAP-SCM questionnaires as well as the patient good days diary are assessed at Baseline and every 3-4 weeks up until 24 weeks post-randomisation and then every 6-8 weeks until the patient's death.
The PROMIS-ED questionnaire is assessed at Baseline, at 6-8 weeks post-randomisation, at 12-16 weeks post-randomisation and then every 12 weeks until the patient's death.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>OS is defined as the interval from the date of randomisation to date of death from any cause or to a minimum of 6 months post randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite of carer related outcomes including carer satisfaction and carer burden from Carer Reaction Assessment (CRA), Clinical Care Tasks measure (CCT), FAMCARE-2, Quality of Death and Dying Questionnaire (QODD).</outcome>
      <timepoint>The CRA and CCT questionnaires are assessed at Baseline and every 3-4 weeks up until 24 weeks post-randomisation (of the patient) and then every 6-8 weeks until the patient's death.
The FAMCARE-2 questionnaire is assessed at 6-8 weeks post-randomisation, at 12-16 weeks post-randomisation and then every 12 weeks until the patient's death.
The QODD questionnaire is assessed at 6-12 weeks after the patient's death.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient and carer understanding of illness and prognosis (using a non-validated 2-item questionnaire used in Temel et al, 2011)</outcome>
      <timepoint>The Patient and carer understanding of illness and prognosis is assessed at Baseline and every 3-4 weeks up until 24 weeks post-randomisation (of the patient) and then every 6-8 weeks until the patient's death.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of end of life care, including use of advance care plans (ACP) and the use of aggressive therapies in the last month of life obtained from the patient's medical record.</outcome>
      <timepoint>Following death of participant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality-adjusted overall survival (using the EQ-5D-5L questionnaire)</outcome>
      <timepoint>The EQ-5D-5L questionnaire is assessed at Baseline and every 3-4 weeks up until 24 weeks post-randomisation and then every 6-8 weeks until the patient's death.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Adults, aged 18 years and older, with a histological or cytological diagnosis within the last
60 days of either:
 (a) Advanced NSCLC (this includes de novo stage IV disease, recurrent NSCLC after definitive treatment, and locally advanced disease which is not planned for curative
treatment), or
 (b) Extensive stage SCLC, or
 (c) Advanced MPM which is not planned for extrapleural pneumonectomy or pleurectomydecortication.

2. Australia-modified Karnofsky performance status of 50 to 100 at the time of randomisation

3. Willing and able to comply with all study requirements, including ability at the time of
screening to complete the QOL questionnaires without assistance, in accordance with
protocol requirements.

4. Signed, written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Immediate referral to palliative care required, or already referred to palliative care (this
includes referral to a community or hospital based palliative care service, or palliative care
physician).

2. Life expectancy of less than 3 months.

3. Serious medical or psychiatric onditions that might limit the ability of the patient to comply with the protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Randomisation by Flexetrials randomisation software.
Stratified allocation employed.
Patients are stratified using: 
1. Cancer type non-small cell lung cancer (NSCLC) which is EGFR or ALK mutation positive
versus NSCLC which is EGFR and ALK mutation negative/unknown versus small cell lung
cancer (SCLC) versus malignant pleural mesothelioma (MPM)
2. Gender
3. Age (younger than 70 years vs 70 years and older)
4. Planned or current use of chemotherapy
5. Australia-modified Karnofsky performance status (70 or lower vs 80 and above)
6. Study site.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>The primary endpoint for this trial is a clinically important improvement in the FACT-L TOI. This is defined as an improvement of 5 points or more from baseline, which is maintained for at least 2 consecutive assessments. The proportion of patients in each arm who achieve the primary endpoint will be reported along with two-sided 95% confidence intervals. A chi-squared test of independence will be performed to test the null hypothesis that the proportions are equal against a two-sided alternative, using a 5%
significance level. Supplementary analyses will include adjustment for stratification factors that were used in the randomisation, as well as consider changes in the raw TOI score over time.

Analyses of secondary endpoints will be performed according to the same principles. Binary outcomes will be presented as proportions and compared using chi-squared tests of independence. Continuous outcomes will be summarised by means or medians and compared using independent t-tests or Wilcoxon rank-sum tests, as appropriate. Time-to-event outcomes will be presented using Kaplan-Meier estimates and compared using a log-rank test. A two-sided 5% significance level will be used for all tests and there
will be no formal adjustment for multiple comparisons, but statistically significant differences in secondary outcomes will be interpreted conservatively, particularly if the primary analysis is non-significant. Supplementary subgroup and adjusted analyses will be defined in the statistical analysis plan. </statisticalmethods>
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/03/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA,VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <hospital>Barwon Health - Geelong Hospital campus - Geelong</hospital>
    <hospital>Royal Melbourne Hospital - City campus - Parkville</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>The Tweed Hospital - Tweed Heads</hospital>
    <hospital>Campbelltown Hospital - Campbelltown</hospital>
    <hospital>Concord Repatriation Hospital - Concord</hospital>
    <hospital>St John of God Midland Public Hospital - Midland</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Toowoomba Hospital - Toowoomba</hospital>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>Maryborough Hospital - Maryborough</hospital>
    <hospital>The Townsville Hospital - Douglas</hospital>
    <hospital>The Chris Oâ€™Brien Lifehouse - Camperdown</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>St Vincent's Hospital (Melbourne) Ltd - Fitzroy</hospital>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2485 - Tweed Heads</postcode>
    <postcode>2560 - Campbelltown</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>6056 - Midland</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>4350 - Toowoomba</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>4650 - Maryborough</postcode>
    <postcode>4814 - Douglas</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>South Island</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW 1450
</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Australia</fundingname>
      <fundingaddress>Level 14, 300 Elizabeth Street
SYDNEY
NSW 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this trial is to evaluate whether early referral for palliative care can improve quality of life, cost effectiveness and quality of end of life care for adults who are newly diagnosed with advanced lung cancer.

Who is it for?
You may be eligible to enroll in this trial if you are aged 18 or over and have been diagnosed with advanced non-small cell lung cancer, extensive small cell lung cancer or advanced malignant pleural mesothelioma within the last 60 days.

Study details
All participants enrolled in this trial will be randomly allocated (by chance) to receive either standard care referral to palliative care at the discretion of the treating oncologist, or to receive early referral to palliative care within 7 days of enrolling in this trial. With the exception of the timing of the referral, the palliative care received by each group will be as per standard care, with information and care provided by the palliative care team as required for each participant.

Participants will be asked to complete a number of questionnaires relating to quality of life and cancer symptoms at regular time points until their death. Carers will be asked to complete quality of life and death questionnaires and an interview at regular intervals up to six months following participant death.

It is anticipated that the findings from this trial will provide information on whether early referral to palliative care following diagnosis of advanced lung cancer is beneficial for patient quality of life and end of life, and cost-effectiveness of care.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>Patients will be asked at screening to nominate a carer who would be willing to complete study assessments. A carer may be any person (including a relative or friend) whom the patient:
(a) Perceives to be their main support person (primary carer)
(b) Agrees for the research team to approach for potential research participation; and
(c) Is agreeable to have their medical information shared.
Written informed consent must be signed and dated by the carer, and signed and dated by the Investigator, prior to any trial-specific carer assessments being completed.
It is preferable for patients to have a nominated carer however patients unable to nominate a carer who are willing to complete the trial assessments will still be eligible for the trial.</publicnotes>
    <ethicscommitee>
      <ethicname>Sydney Local Heatlh District (RPAH Zone) Ethics Review Committee</ethicname>
      <ethicaddress>Research Ethics and Governance Office
Royal Prince Alfred Hospital
Missenden Road
Camperdown 
NSW 2050</ethicaddress>
      <ethicapprovaldate>25/10/2016</ethicapprovaldate>
      <hrec>X16-0340 &amp; HREC/16/RPAH/467</hrec>
      <ethicsubmitdate>8/08/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371931-PEARL_Protocol_V1.0_dated_050816.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371931-PEARL_X16-0340_central_HREC_approval_251016.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371931-PEARL_Participant_PICF_v1.1_061016_clean.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/371931-PEARL_MASTER_Carer_PICF_v1.1_171016.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Linda Mileshkin</name>
      <address>Peter MacCallum Cancer Centre
305 Grattan Street, 
Melbourne VIC 3000</address>
      <phone>+61 3 8559 5000</phone>
      <fax>+61 3 8559 7739</fax>
      <email>linda.mileshkin@petermac.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>David Cannan</name>
      <address>NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>pearl@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Linda Mileshkin</name>
      <address>c/o PEARL Study Team
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>pearl@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>David Cannan</name>
      <address>NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>pearl@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>